BiotechTube
Aqur Biosciences

Aqur Biosciences

San Diego, United States· Est.
aqurbiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Aqur Biosciences is a private, preclinical-stage biotech company founded in 2019, targeting the vast cardiovascular disease market with a novel oral therapy. The company's lead candidate, AQR-008, is an oral PCSK9-pathway modulator designed to be a more user-friendly and accessible option for managing high cholesterol. Operating from Southern California, Aqur is in the early stages of research and development, positioning itself in a competitive landscape dominated by injectable PCSK9 inhibitors. Its success hinges on demonstrating clinical efficacy and differentiation for its oral approach.

CardiovascularMetabolic Disorders

Technology Platform

Oral small molecule modulation of the PCSK9 pathway for cholesterol management.

Funding History

1
Total raised:$12M
Series A$12M

Opportunities

The global market for cholesterol-lowering drugs is massive, with a significant unmet need for convenient, effective oral therapies.
A successful oral PCSK9 inhibitor could achieve high patient and physician preference due to its ease of use compared to injectables, potentially capturing a multi-billion dollar market segment.
Early success could position the company as an attractive partner or acquisition target for larger pharma.

Risk Factors

The core scientific risk is the high failure rate of early-stage drug discovery, particularly for oral PCSK9 inhibitors which have proven historically challenging.
The company faces intense competition from established injectable PCSK9 therapies and other oral agents, and its pre-revenue status makes it dependent on risky future financing rounds to survive.

Competitive Landscape

The competitive landscape is dominated by injectable PCSK9 monoclonal antibodies (Repatha, Praluent) and the twice-yearly injectable siRNA Leqvio. Oral competitors include bempedoic acid (Nexletol) and generic statins. Several other biotech and pharma companies are also pursuing oral PCSK9 inhibitors, making it a competitive and high-stakes field.

More companies in Small Molecule Drugs →More companies in United States →